Retrophin, LLC Unveils New Clinical Development Candidate RE-034, An ACTH Analog

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK--(BUSINESS WIRE)--Retrophin, Inc. (OTCQB: RTRX) today announced its newest clinical development candidate RE-034 (cosyntropin), a long-acting synthetic analog (amino acids 1-24) of the naturally-occurring adrenocorticotropic hormone (ACTH) formulated with zinc. Cosyntropin is also known outside the U.S. as tetracosactide.

Help employers find you! Check out all the jobs and post your resume.

Back to news